Interim Effectiveness of the Influenza Vaccine for the 2024-2025 Respiratory Viral Season
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The purpose of this study was to evaluate the effectiveness of the influenza vaccine during the 2024-2025 viral respiratory season.
Methods
Employees of Cleveland Clinic in employment in Ohio on October 1, 2024, were included. The cumulative incidence of influenza among those in the vaccinated and unvaccinated states was compared over the following weeks. Protection provided by vaccination (analyzed as a time-dependent covariate) was evaluated using Cox proportional hazards regression. The analysis was adjusted for age, sex, job type, employment location, and eagerness to get vaccinated.
Results
Among 53321 employees, 43771 (82.1%) had received the influenza vaccine by the end of the study. Influenza occurred in 324 (0.6%) during the study. In an analysis adjusted for age, sex, job type, employment location, and eagerness to get vaccinated, the risk of influenza was not significantly different between the vaccinated and unvaccinated states (HR, 1.10; 95% C.I., .77 - 1.57; P = 0.59), yielding a calculated vaccine effectiveness of −10.1% (95% C.I. −57.0 - 22.7%).
Conclusions
This study has been unable to find that the influenza vaccine given to working-aged adults has provided protection overall against influenza during the 2024-2025 respiratory viral season thus far.
Summary
Among 53321 working-aged Cleveland Clinic employees, we were unable to find that the influenza vaccine has been effective in preventing infection during the 2024-2025 respiratory viral season thus far.
